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Stefania pagani1, Manuela Minguzzi2,3, Laura Sicuro  1, francesca Veronesi1, 
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osteoarthritis (oA), the most prevalent degenerative joint disease, still lacks a true disease-modifying 
therapy. the involvement of the nf-κB pathway and its upstream activating kinases in oA pathogenesis 
has been recognized for many years. The ability of the N-acetyl phenylalanine glucosamine derivative 
(NAPA) to increase anabolism and reduce catabolism via inhibition of IKKα kinase has been previously 
observed in vitro and in vivo. The present study aims to confirm the chondroprotective effects of 
nApA in an in vitro model of joint OA established with primary cells, respecting both the crosstalk 
between chondrocytes and synoviocytes and their phenotypes. This model satisfactorily reproduces 
some features of the previously investigated DMM model, such as the prominent induction of 
ADAMTS-5 upon inflammatory stimulation. Both gene and protein expression analysis indicated the 
ability of NAPA to counteract key cartilage catabolic enzymes (ADAMTS-5) and effectors (MCP-1). 
Molecular analysis showed the ability of NAPA to reduce IKKα nuclear translocation and H3Ser10 
phosphorylation, thus inhibiting IKKα transactivation of nf-κB signalling, a pivotal step in the nf-κB-
dependent gene expression of some of its targets. In conclusion, our data confirm that NAPA could truly 
act as a disease-modifying drug in oA.
Osteoarthritis (OA), considered for many decades a chronic degenerative disease and more recently, an inflam-
matory disease, is the most diffuse rheumatic disease, affecting up to 15% of the adult population worldwide1. 
OA is characterized by a progressive degradation of the extracellular matrix (ECM) of articular cartilage until its 
complete erosion and uncovering of the subchondral bone (SB)2. The vicious cycle that is established starts with a 
weak matrix alteration, the subsequent response by chondrocytes and synoviocytes in terms of pro-inflammatory 
cytokine release, the activation of some transcription factors, and finally the production of catabolic mediators 
such as metalloproteases (MMPs) and aggrecanases. The increasing inflammatory state leads to an imbalance 
between the synthesis and degradation of extracellular matrix components. This inflammation leads to poor 
quality of life, pain and decreased joint functionality for the patients3–5.
Even if some mechanisms underlying cartilage destruction are known, many are still not clearly identified. 
Among the key players of intracellular pathways, a well-known actor is nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB). NF-κB is a complex of five different subunits that acts as a transcription factor by the 
assembly of alternative homodimers and heterodimers, thus inducing gene transcription of many inflammatory 
cytokines. The removal of IκB inhibitors from the cytoplasmic NF-κB complex by the activated kinases IKKα or 
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IKKβ allows the translocation of NF-κB dimers into the nucleus and the consequent transcription of inflamma-
tory mediators and catabolic enzymes, such as interleukin (IL)-6, IL-8, and MMPs6,7. A prolonged inflammatory 
state provokes the loss of the growth-arrested state of articular chondrocytes, deregulated gene expression, and 
consequent cartilage degradation8.
Despite the widespread occurrence of OA, to date, a therapy able to heal this chronic pathology is lacking. 
The current management of patients includes physical exercise, rehabilitation, and known pharmacological 
agents: analgesics, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and corticoids. However, these 
approaches can only treat symptoms, rather than the underlying process, at best improving functionality and 
pain7,9. Therefore, the need to develop therapies aimed at preventing, delaying or defusing joint inflammation and 
degenerative progression remains great.
As a possible alternative, several chondroprotective agents have been recently studied: glucosamine (GlcN), 
chondroitin sulphate, diacerein and curcumin10–12, in addition to hyaluronic acid (HA) for viscosupplementation 
intervention9.
Several in vitro studies have already underlined the positive effects of GlcN, an essential compound of most 
cartilage proteoglycans; it inhibits NF-κB and activator protein 1 (AP-1) activation13,14, IL-6, iNOS, COX-212, and 
PGE2 release15,16, MMPs and collagenase activity17, while stimulating aggrecan synthesis18. However, in addition 
to a large body of encouraging evidence that supported decades of clinical use of GlcN as a treatment for OA, 
negative or contradictory effects have also been reported, both in vitro17,19 and in vivo 20–22.
In this regard, the synthesis and selection of 2-(N-acetyl)-L-phenylalanylamido-2-deoxy-β-D-glucose 
(NAPA), among the GlcN derivatives, was related to its higher bioavailability compared with GlcN at the intra-
cellular level, due to the hydrophobic character imparted by the aromatic ring of phenylalanine. NAPA seems to 
exert better anti-inflammatory and chondroprotective activity compared to GlcN, according to recent studies 
highlighting their differential roles in the intracellular inflammatory pathway5,13.
The results obtained with human and rabbit primary and immortalized chondrocytes showed interesting 
effects on inflammatory cytokines under NF-κB control, such as IL-6 and IL-85. Both GlcN and NAPA effectively 
counteracted the negative effects of IL-1β and TNFα administration, reducing matrix metalloproteinase produc-
tion and reverting the gene expression of IL-6 and IL-8. Conversely, the inhibition of IKKα kinase activity was 
exerted only by NAPA, whereas the inhibition of IKKα nuclear re-localization due to both chondroprotective 
compounds5.
We recently reported the effectiveness of intra-articular delivery of NAPA in reducing OA progression in 
a murine surgical OA model obtained by destabilization of the medial meniscus (DMM)7. The in vivo studies 
demonstrated the efficacy of NAPA for OA treatment as evaluated by histology, histomorphometry and immuno-
histochemical assessment of some selected markers (MMP-13, ADAMTS5, MMP-10 and IKKα).
Notably, in the in vivo model, NAPA administration was performed at 4 weeks post-DMM, a time that cor-
responds to a mild-to-moderate OA (4 weeks), i.e., a disease stage that in human OA could be more amenable to 
disease-modifying treatments compared to the moderate-to-severe stage. This setting can be mimicked in vitro by 
sustained stimulation with IL-1β that, in our experimental design, preceded the addition of NAPA. Interestingly, 
in OA onset and development, a crucial role is played by the synovial-to-cartilage crosstalk23 that we aimed to 
reproduce in the present paper using a co-culture system. Therefore, compared to other in vitro studies, the 
present study proposed a different culture system and stimulation timing to develop a more realistic model, 
which is the closest possible to our previous in vivo study. NAPA administration was performed some days after 
inflammatory induction to better reproduce the real timing of a pharmacological treatment to a joint at the stage 
known as “early OA”.
Chondrocytes and synoviocytes, derived from either healthy or OA donors, were used and kept in co-culture. 
To explore the effects of the inflammatory stimulus and NAPA treatment in a “site specific manner”, we evalu-
ated both chondrocytes and synoviocytes for changes in gene expression, while analysis of protein content was 
possible only for chondrocytes that were evaluated for changes in signalling and effector molecules. Moreover, 
our analysis included the cumulative contribution of chondrocytes and synoviocytes to the supernatant, thus 
mimicking a synovial fluid-like environment. Pivotal inflammatory and matrix degrading molecules were investi-
gated both at the level of gene transcription (in both chondrocytes and synoviocytes) and protein release. To gain 
further insight into NAPA activity, we explored the underlying molecular mechanisms from the perspective of 
translating the findings to the treatment of human OA. Therefore, the effects on chondrocytes of NAPA delivery 
to co-cultures were evaluated by immunofluorescence to assess the level of IKKα nuclear expression and by both 
western blot and immunofluorescence to determine the extent of phosphorylated serine 10 of histone H3.
Materials and Methods
cell cultures. Experiments were performed with commercially available chondrocytes and synoviocytes of 
either healthy or OA origin, in accordance with relevant guidelines and regulations (Rizzoli Orthopaedic Institute 
has kept the ISO 9001 Quality certification since 2008, with special reference to the Research area). Co-cultures 
of primary chondrocytes and synoviocytes were set up in 24-well plates to test the anti-inflammatory effects of 
NAPA.
First, NHC-a (normal human chondrocytes –adult) or HC-OA (human chondrocytes-osteoarthritis) pur-
chased from Cell Application (San Diego, CA, USA) were seeded at a density of 5 × 104/cm2 on the well bottom, 
maintained in complete differentiating medium (CDBM, LONZA Walkersville, MD, USA) containing 5% foe-
tal bovine serum (FBS), supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich, 
Arklow, Ireland), and cultured for 1 week to reach a hyperconfluent status24.
After reaching this status, HFLS (human fibroblast-like synoviocytes) or HFLS-OA (human fibroblast-like 
synoviocytes –osteoarthritis) (Cell Application) were seeded at a density of 4 × 104/cm2 onto the bottom of a 
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polyester cell culture insert (COSTAR, Corning Incorporated, Kennebunk, ME, USA; surface area 0.33 cm2) in a 
mixture of Dulbecco’s Modified Eagle’s Medium (DMEM) and F12 supplemented with 10% FBS.
The following day, the co-cultures were assembled, and the inflammatory stimulation (10 ng/ml recombinant 
interleukin (IL)-1β (PeproTech EC Ltd., London, UK)) was started in two-thirds of the wells and maintained for 
one week. Then, after changing the medium, the IL-β-treated wells were again maintained with 10 ng/ml IL-1β, 
but half of these IL-1β-treated wells were also treated with NAPA; its effects were investigated at 0, 8, 24 and 
48 hours. Therefore, the cells left untreated for one week and after the medium change represented the control 
(CTR), and the cells treated with IL-1β for 1 week and after the medium change represented the inflammatory 
condition (IL-1β), while the cells treated for 1 week with IL-1β and subsequently treated with a single dose of 
5 mM NAPA, in addition to IL-1β, represented the treated condition (NAPA). Each condition was carried out in 
triplicate wells.
Three independent experiments were carried out with normal cells, and two independent experiments were 
carried out with OA cells.
All evaluations were performed at the time of NAPA administration (T zero or basal) and after 8, 24 and 
48 hours.
Cell viability. To evaluate cell viability at each time-point, the cultures of chondrocytes and synoviocytes 
were disassembled, and Alamar blue dye (Serotec, Oxford, UK) was added to the media of CTR and experimental 
conditions (1:10 v/v) and incubated for 4 hours at 37 °C.
The reagent is a dye that incorporates an oxidation-reduction (REDOX) indicator that changes colour in 
response to chemical reduction of the growth medium that is proportional to cell growth. The fluorescence was 
read at 530ex-590em nm wavelengths by a Micro Plate reader (VICTOR X2030, Perkin Elmer, Milan, Italy) and 
expressed as relative fluorescence units (RFU). For each experiment, the data were normalized for the values of 
the non-stimulated control at T0.
Gene expression. Total RNA was extracted separately from chondrocytes and synoviocytes with the 
PureLink RNA mini kit (Ambion), quantified by a NANODROP spectrophotometer (NANODROP 2720, 
Thermal Cycler, Applied Biosystem) and reverse transcribed with the Superscript VILO cDNA Synthesis kit (Life 
Technologies) according to the manufacturer’s instructions. Each sample was diluted to a final concentration of 
5 ng/μl, taking into account the starting amount of RNA, to exploit the same range of amplification efficiency. 
Gene expression was evaluated by semi-quantitative PCR analysis using the SYBR Green PCR kit (Qiagen) in 
a Light Cycler 2.0 instrument (Roche Diagnostics). Five nanograms of each sample was tested in duplicate. The 
protocol included a denaturation cycle at 95 °C for 15 min, 25–40 cycles of amplification (95 °C for 15 s, appropri-
ate annealing temperature for each target, as detailed in Table 1, for 20 s, and 72 °C for 20 s) and a melting curve 
analysis to check for amplicon specificity.
In an effort to correlate NAPA activity with gene expression, a broad spectrum of genes has been analysed 
in both cellular types. To better appreciate the trend of RNA accumulation and the basal level of expression, we 
chose to express transcription by the 2−ΔCt method25 and presented the results in terms of the number of mole-
cules of the gene of interest per 100000 molecules of the housekeeping gene GAPDH. Each evaluation was per-
formed on three replicate cultures. The extracted RNA was pooled and processed. Each experimental condition 
was then tested in duplicate.
protein release. The supernatants harvested at all time points from the triplicate wells containing the 
co-cultures of chondrocytes and synoviocytes were centrifuged to eliminate particulates and maintained at 
−80 °C until the evaluation. Immunoenzymatic assays (ELISA) were employed to quantify the amount of Tumour 
Necrosis Factor α (TNFα) and Interleukin 6 (IL-6), (CLOUD USCN Life Science), according to the manufactur-
er’s instructions. Moreover, the release in the supernatants of a panel of four chemokines (CCL-2/MCP-1, CCL-5/
RANTES, CCL-3/MIP-1α and CCL-4/MIP-1β) and a wide panel of metalloproteases (MMP-1, MMP-2, MMP-3, 
MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, MMP-13) was quantified by using a Bio-Plex Pro assay (BIO-RAD 
Laboratories) that exploits a bead-based sandwich immunoassay technology with high sensitivity and dynamic 
range.
Western blot. To achieve effective extraction of both nuclear and cytoplasmic proteins, including those 
bound to DNA, radioimmunoprecipitation (RIPA) buffer with the addition of benzonase and protease inhibitor 
cocktail (PIC; Sigma-Aldrich) was used to extract proteins from the pellets of the cells recovered from each well. 
The composition of the buffer was as follows: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 
0.5% Na deoxycholate, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 1:200 PIC, and 100 U/ml benzonase. Briefly, total 
cellular lysates were obtained by solubilizing the cells with RIPA buffer in addition to vigorous homogenization 
with disposable pestles (Sigma) and vortexing.
A volume of lysate corresponding to 160000 cells was loaded in the wells of Nu-Page precast 4–10% poly-
acrylamide gels (Invitrogen), which were subsequently transferred onto polyvinylidene fluoride membranes by 
a dry electroblotting method using an I-Blot (Invitrogen). Then, the blots were subjected to immunodetection 
using a SNAP-ID 2.0 device (Merck Millipore). Signals were detected with appropriate secondary antibodies 
and visualized with ECL Select (Amersham) using the CCD camera acquisition system of a ChemiDoc Imaging 
Systems apparatus (BioRad). Western blot images were then analysed by means of a Carestream Molecular 
Imaging Software 5.0 (Carestream Health, Inc.) to accurately and automatically assess the molecular weight of 
the bands, using a proper molecular weight marker (Novex Sharp Pre-stained Protein Standard, Invitrogen). 
Semi-quantitative analysis of band intensity was performed considering “optical density” values and using 
QuantityOne software (BioRad).
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The following primary antibodies were used: anti-phospho-histone H3, (Ser10), (mouse monoclonal, 
Upstate–Millipore); anti-ADAMTS5, (rabbit polyclonal, Millipore); and anti-NFKB1 (p105/p50) (rabbit poly-
clonal, Abcam). Anti-GAPDH (mouse monoclonal, Merck Millipore) served as a loading control. Appropriate 
anti-species antibodies and HRP-conjugated antibodies were from Jackson laboratories.
Immunofluorescence. Experiments were carried out to better appreciate the subcellular IKKα distribution 
in chondrocytes in all the previously described conditions.
At first, this analysis was carried out with cells cultured in parallel with those used for gene expression and 
protein analysis, i.e., in 24-well plates. Images of these experiments were observed by means of an inverted Nikon 
Eclipse TiU equipped with 530ex/580em filters to evaluate IKKα stained with a red emitting fluorochrome, while 
nuclear counterstaining with DAPI was evaluated with 360ex/460em filters. Additional experiments were per-
formed to observe the IKKα subcellular distribution in conjunction with the extent of phosphorylation of Ser10 
in Histone H3 by double immunofluorescence labelling. For this purpose, chondrocytes were seeded onto round 
coverslips placed in the wells of a 24-well plate to subsequently permit glass removal, processing and image acqui-
sition by means of both a NIKON Eclipse 90i fluorescence microscope and a NIKON confocal microscope system 
A1, essentially as previously described26. The hyperconfluent cultures of chondrocytes under all conditions were 
washed with PBS (phosphate-buffered saline) and fixed with 4% paraformaldehyde for 30 min at RT. The samples 
were pre-treated for antigen unmasking with 0.02 U/ml Chondroitinase ABC (SIGMA) in 50 mM Tris/HCl pH 
8.0 for 20 min at 37 °C and permeabilized with 0.2% Triton in TBS (TRIS-buffered saline) solution for 5 min at 
RT. After extensive washes with TBS, the non-specific bindings were blocked with 5% BSA (bovine serum albu-
min), 5% normal donkey serum and 0.1% Triton in TBS for 30 min at RT and washed again. IKKα staining was 
performed with 5 µg/ml rabbit anti-IKKα antibody (BOSTER Biological Technology, Freemont, CA, USA), while 
the extent of phosphorylation of serine 10 of histone H3 was evaluated with 5 µg/ml anti-phospho-histone H3, 
(Ser10), (mouse monoclonal, Upstate–Millipore) overnight at 4 °C. After rinsing in TBS, the signal was visual-
ized with 15 µg/ml Alexa Fluor® 555 donkey anti-rabbit and 15 µg/ml Alexa Fluor® 488 donkey anti-mouse IgG 
secondary antibody conjugates (Novex), incubated for 30 min at RT together with 1 µg/ml Hoechst 33342 (Sigma 
Aldrich) for nuclear counterstaining. Finally, the samples were mounted with the addition of anti-fading reagent 
(1% 1,4 Diazobicyclo (2.2.2) Octane (DABCO, SIGMA) in 90% glycerol in 0.1 M pH 8.0 Tris-HCl), sealed with 
nail polish and stored refrigerated and in the dark for subsequent analysis.
The acquisition of Alexa 488-labelled anti-hIKKα antibody, Alexa 555-labelled anti-phospho-histone H3 
(Ser10) and Hoechst 33342-labelled DNA signals was also performed using an A1-R confocal laser scanning 
GENE Forward primer Reverse primer
Amplicon 
Length
Annealing 
Temperature
Cell 
type
GAPDH 5′-TGGTATCGTGGAAGGACTCA-3′ 5′-GCAGGGATGATGTTCTGGA -3′ 123 bp 56 °C C, S
MMP1 5′-GACAGAGATGAAGTCCGGTTT-3′ 5′-GCCAAAGGAGCTGTAGATGTC-3′ 102 bp 60 °C C, S
MMP3 5′-CACAGACCTGACTCGGTTCC-3′ 5′-AAGCAGGATCACAGTTGGCT-3′ 152 bp 60 °C C, S
MMP8 5′-GCTTCCATTTCTGCTCTTACTC-3′ 5′-GCCATTCTTCCTTGTAGACTGA-3′ 215 bp 60 °C C
MMP10 5′-GCCAGTCCATGGAGCAAGGCT-3′ 5′-TCGCCTAGCAATGTAACCAGCTGT-3′ 195 bp 58 °C C, S
MMP13 5′-AGCCACTTTATGCTTCCTGA-3′ 5′-TGGCATCAAGGGATAAGGAAG-3′ 130 bp 60 °C C, S
ADAMTS 4 5′-CTGCCTACAACCACCG-3′ 5′-GCAACCAGAACCGTCC-3′ 293 bp 58 °C C, S
ADAMTS 5 5′-GCACTTCAGCCACCATCAC-3′ 5′-AGGCGAGCACAGACATCC-3′ 187 bp 58 °C C, S
TIMP 3 5′-CCTTGGCTCGGGCTCATC-3′ 5′-GGATCACGATGTCGGAGTTG-3′ 121 bp 60 °C C
IL 1β QuantiTect Primer Assay (Qiagen) Hs_IL1B_1_SG 117 bp 55 °C' C
IL 6 5′-GCAGATGAGTACAAAAGTCCTGA-3′ 5′-TTCTGTGCCTGCAGCTTC-3′ 120 bp 60 °C C, S
IL 8 5′-ATGACTTCCAAGCTGGCCGTG-3′ 5′-TTATGAATTCTCAGCCCTCTTCAAAAACTTCTC-3′ 300 bp 60 °C C, S
IL 10 5′-GCGCTGTCATCGATTTCTTC-3′ 5′-TCACTCATGGCTTTGTAGATGC-3′ 108 bp 60 °C S
TNFα QuantiTect Primer Assay (Qiagen) Hs_TNF_1_SG 104 bp 55 °C C, S
GROα 5′-ATTCACCCCAAGAACATCC-3′ 5′-GATTTGTCACTGTTCAGCATC-3′ 164 bp 56 °C C
MCP1 5′-GAAGCTCGCACTCTCGCCT-3′ 5′-GAGTGTTCAAGTCTTCGGA-3′ 330 bp 56 °C C,S
RANTES 5′-AGGTACCATGAAGGTCTCC-3′ 5′-GACTCTCCATCCTAGCTCA-3′ 294 bp 56 °C C,S
IKKα QuantiTect Primer Assay (Qiagen) Hs_CHUK_1_SG 109 bp 55 °C C
NFKB1 5′-CAGGAGACGTGAAGATGCTG-3' 5′-AGTTGAGAATGAAGGTGGATGA-3' 109 bp 60 °C C,S
RELA 5′-CGAGCTTGTAGGAAAGGACTG-3' 5′-TGACTGATAGCCTGCTCCAG-3' 132 bp 60 °C C,S
NFKBIA 5′-TCCTGAAGGCTACCAACTACA-3' 5′-CATTGACATCAGCACCCAAG-3' 108 bp 60 °C C,S
iNOS 2 QuantiTect Primer Assay (Qiagen) Hs_NOS2_1_SG 92 bp 55 °C C
SOX 9 5′-GAGCAGACGCACATCTC-3′ 5′-CCTGGGATTGCCCCGA-3′ 118 bp 60 °C C
ACAN 5′-TCGAGGACAGCGAGGCC-3′ 5′-TCGAGGGTGTAGCGTGTAGAGA-3′ 85 bp 60 °C C
COL2A1 GTTTTCCAGCTTCACCATCATC CCTCAAGGATTTCAAGGCAAT 121 bp 60 °C C
Table 1. Details of primers used for gene expression analysis. The letters C: chondrocytes and S: synoviocytes, 
specify the cell type in which the gene expression was analyzed.
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microscope (Nikon), equipped with a Nikon 60x, 1.4 NA objective, and with 405, 488 and 561 nm laser lines to 
excite Hoechst 33342 (blue), Alexa 488 (green) and Alexa 555 (red) fluorescence signals, respectively.
Emission signals were detected by a photomultiplier tube (DU4) preceded by emission filters BP 525/50 nm 
and BP 595/50 nm for Alexa Fluor 488 and Alexa Fluor 555, respectively. Laser scanning, image acquisition and 
processing were performed with Nikon Imaging Software NIS Elements AR-4 (Nikon Inc., USA). Optical sections 
were spaced *0.3 µm along the z axis and were digitized with a scanning mode format of 1024 × 1024 pixels and 
4096 grey levels. Both optical sections and 3D projection images were obtained.
Statistics. The graphs represent the cumulative analysis of at least four different experiments or otherwise 
stated in the Figure Legend. All data are presented as the mean ± standard deviation (SD) and analysed and 
graphed using GraphPad Prism version 5.00 for Windows (GraphPad Software).
An initial screening was carried out at time 0 to compare each IL-1β condition versus the paired CTR condi-
tion. The means of groups were compared with two-tailed Student’s t test for paired samples, and the differences 
were considered significant when P < 0.05, with *P < 0.05; **P < 0.01; and ***P < 0.001. Then, at each time 
point of NAPA treatment (8, 24 and 48 hours), since comparisons were undertaken among multiple groups (CTR, 
IL-1β-treated and IL-1β + NAPA-treated samples), ANOVA was used, followed by Tukey’s post hoc test. Again, 
the differences were considered significant when P < 0.05 when comparing multiple groups, but different sym-
bols were used for different comparisons: #P < 0.05; ##P < 0.01; and ###P < 0.001 were used to score the degree 
of significance of the differences of either IL-1β treatment or IL-1β + NAPA treatment compared to the control 
condition and *P < 0.05; **P < 0.01; and ***P < 0.001 were used for IL-1β treatment compared to IL-1β + NAPA 
treatment.
Results
IL-1β or NAPA treatment does not affect cell viability. The viability assessment performed on both 
chondrocyte and synoviocyte cultures used for the co-culture setting did not reveal significant differences among 
the groups for both healthy and osteoarthritic cells or across the different time points (Fig. 1). This observation 
allowed us to exclude toxic effects of NAPA on the cultures, in keeping with previous findings5. Moreover, the 
additional evidence that the different treatments produced similar effects on both healthy and OA chondrocytes 
allowed us to present the results cumulatively, as described thereafter.
IL-1β delivery to co-cultures of chondrocytes and synoviocytes reproduces an oA joint environ-
ment, and NAPA reduces the expression of pivotal OA effectors. 
•	 Gene expression
IL-1β strongly upregulates gene expression of catabolic and inflammatory genes in chondrocytes and synoviocytes. 
Based on the known anti-inflammatory activity of GlcN, which is able to modulate the NF-κB signalling pathway 
and its target genes, the effect of its NAPA derivative was at first assessed on the expression of a wide range of 
NF-κB-dependent genes with a pivotal role in OA pathophysiology, including catabolic enzymes and inflam-
matory molecules (cytokines and chemokines). A selection of genes was investigated in both chondrocytes and 
synoviocytes, as detailed in Table 1. Other genes were only assessed in chondrocytes since their higher number 
allowed for a higher cDNA yield.
IL-1β markedly increased the expression of most of the analysed genes at T0 (Supplementary Figs 1, 2 and 3), 
thus confirming the suitability of the in vitro model. Some genes were found to be elevated by IL-1β treatment 
in both chondrocytes and synoviocytes. IL-1β significantly increased chondrocyte expression of many cat-
abolic enzymes (Supplementary Fig. 1: MMP-3, MMP-10, MMP-1, and ADAMTS5), cytokines and chemok-
ines (Supplementary Fig. 2: IL-1β, TNFα, IL-6, MCP-1, IL-8 and GROα) and NFKB1 (Supplementary Fig. 3), a 
Figure 1. IL-1β or NAPA treatments do not affect cell viability. At each time point, before extraction for gene 
expression analysis, the co-cultures of chondrocytes and synoviocytes were disassembled, and Alamar blue 
dye was added to the media of CTR and treated samples (experimental conditions) (1:10 v/v) and incubated 
for 4 hours at 37 °C. Then, the fluorescence was read, and the values for each experiment (expressed as relative 
fluorescence units) were normalized for the values of the unstimulated control at T0. The left graph shows 
chondrocyte viability, while the right graph shows synoviocyte viability (mean ± standard deviation, n = 4).
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protein that is both an NF-κB member and a known NF-κB target gene27, thus further confirming that culture 
conditions elicited NF-κB activation. Moreover, despite failing to reach statistical significance, IL-1β stimulation 
led to reduced expression of Sox-9 and collagen 2A1, as previously reported28. The expression of TNFα and IL-6 
was also significantly increased in synoviocytes.
NAPA reduces the gene expression of key OA effectors in chondrocytes and synoviocytes. Conversely, the addi-
tion of NAPA decreased the chondrocyte expression of most of these genes at 24 hours: ADAMTS5, the piv-
otal matrix-degrading enzymes in osteoarthritis (Fig. 2) and IL-6 and MCP-1 (Fig. 3). Compared with IL-1β 
treatment, the addition of NAPA significantly decreased the expression of ADAMTS5 at both 8 and 24 hours 
(p < 0.01), while MMP13 showed a mild reduction at 24 hours that was not statistically significant. Moreover, 
NAPA addition significantly reduced IL-6 and MCP-1 (p < 0.05), while TNFα was reduced at 24 hours with 
NAPA treatment.
Additionally, in synoviocyte cultures, the expression of IL-6 was significantly modulated by NAPA after 
24 hours.
To further explore the effects of NAPA in the NF-κB signalling pathway, we investigated the chondrocyte 
gene expression of three molecules with a role in this pathway: the NF-κB proteins NFKB1 (p105-50) and RelA 
(p65) and the main inhibitor of this pathway NFKBIA (IκBα). Previous literature has indicated that p105-50 and 
IκBα are NF-κB targets27. NAPA treatment modulated p105-50 at both 8 and 24 hours (p < 0.001 and p < 0.05, 
respectively, Fig. 4), while RelA was unaffected. NFKBIA gene expression paralleled that of NFKB1 but failed 
to reach statistical significance. The NAPA-dependent reduction in NFKB1, a known NF-κB target, is consist-
ent with the NF-κB-inhibiting activity of NAPA. On the other hand, RelA, which is not included among the 
NF-κB-dependent genes, was almost unaffected in both chondrocytes and synoviocytes.
Overall, our data showed a higher expression (in terms of number of molecules relative to those of the house-
keeping gene) of these OA-related genes in chondrocytes compared with synoviocytes, together with a higher 
IL-1β induction and stronger NAPA modulation.
Figure 2. IL-1β strongly upregulates gene expression of pivotal catabolic genes in chondrocytes, and NAPA 
counteracts this effect. Left graphs: MMP-13 and ADAMTS5 gene expression in chondrocytes; middle 
graphs: MMP-13 and ADAMTS5 gene expression in synoviocytes; right framed graphs: protein assessment 
of MMP-13 in the supernatant (above) and of ADAMTS5 (below) in both chondrocyte extract and co-culture 
supernatant [mean ± standard deviation; chondrocytes: n = 8 (4 experiments in duplicate); synoviocytes: n = 4 
(2 experiments in duplicate)]. At each time point of NAPA treatment (8, 24 and 48 hours), the means of groups 
(CTR, IL-1β treated and IL-1β + NAPA treated samples) were compared by ANOVA, followed by Tukey’s post 
hoc test. Different symbols were used for different comparisons: #P < 0.05; ##P < 0.01 and ###P < 0.001 were 
used to score the degree of significance of the differences of either IL-1β treatment or IL-1β + NAPA treatment 
compared to the control condition and *P < 0.05; **P < 0.01; and ***P < 0.001 for IL-1β treatment compared 
to the IL-1β + NAPA treatment.
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•	 Protein expression
NAPA reduces the levels of key OA effectors in the supernatants of the co-cultures. To confirm that NAPA inhibi-
tion of IL-1β-induced transcription was paralleled by effects on the synthesis and release of the same inflamma-
tory markers and matrix degradation effectors, the amounts of these molecules were assessed by enzyme linked 
assays or BIOPLEX technology for released molecules or by western blot for intracellular proteins.
First, IL-1β was confirmed as a powerful inflammatory trigger at the protein level. To date, we have little 
evidence about the efficacy of NAPA and only limited knowledge about the specific mechanisms and pathways 
underlying the anti-inflammatory ability of this innovative drug; therefore, a complete screening of the MMPs 
was performed. Release of MMP-1, -3, -10, -13, -9, -7, and -12 increased after inflammatory stimulation (Fig. 2, 
upper right panel and Supplementary Fig. 4). Eight hours of NAPA treatment led to decreased release of MMP-10, 
MMP-13, MMP-7, although it was not statistically significant.
The pattern of ADAMTS5 was investigated by combining ELISA and western blotting to detect both the intra-
cellular precursor and the released activated enzyme. Western blot analysis was used to assess the ADAMTS5 con-
tent of lysates obtained from the high-density chondrocyte cultures. The western blot in the bottom right panel of 
Fig. 2 shows the 73 kDa protein that corresponds to the active enzyme form yielded by the proteolytic activation 
of the zymogen. This proteolytic activation results in C-terminal truncation, release of the enzyme from the ECM 
and alteration of its activity profile29. The lower graph represents the values assessed by ELISA in the supernatants 
collected from one experiment and suggests that NAPA effectively hampers the release of this pivotal matrix 
degrading enzyme that is induced by inflammatory activation. It is worth emphasizing that in our particular 
experimental model, the prototypical inflammatory stimulus IL-1β strongly enhances ADAMTS5 expression, 
thus mostly approaching what was observed in animal models, rather than with short-term stimulation in vitro30. 
Figure 3. IL-1β strongly upregulates gene expression of pivotal inflammatory genes in chondrocytes, and 
NAPA counteracts this effect. Left graphs: TNF-α, IL-6 and MCP-1 gene expression in chondrocytes; middle 
graphs: TNF-α, IL-6 and MCP-1 gene expression in synoviocytes; right framed graphs: protein assessment of 
IL-6 (above) and MCP-1 (below) in the supernatant of co-cultures [mean ± standard deviation; chondrocytes: 
n = 8 (4 experiments in duplicate); synoviocytes: n = 4 (2 experiments in duplicate)]. At each time point of 
NAPA treatment (8, 24 and 48 hours), the means of groups (CTR, IL-1β treated and IL-1β + NAPA treated 
samples) were compared by ANOVA, followed by Tukey’s post hoc test. Different symbols were used for 
different comparisons: #P < 0.05; ##P < 0.01 and ###P < 0.001 were used to score the degree of significance of 
the differences of either IL-1β treatment or IL-1β + NAPA treatment compared to the control condition and 
*P < 0.05; **P < 0.01; and ***P < 0.001 for IL-1β treatment compared to the IL-1β + NAPA treatment.
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Despite some specific biochemical differences, ADAMTS5 is much more active than ADAMTS429 and is one 
among the few genes causatively correlated with OA pathogenesis by functional genomics and surgically induced 
OA31.
With regard to the inflammatory cytokines, the amounts of TNFα (undetectable in the supernatants) or 
IL-6 (strongly enhanced in the supernatants by IL-1β) were not affected by NAPA treatment. Instead, among 
the chemokines analysed, after 8 hours of NAPA administration, a strong modulation was observed for MCP-1 
(p < 0.001), while milder, but not statistically significant, effects were observed for MIP-1α and MIP-1β (Fig. 3, 
bottom right panel and Supplementary Fig. 5).
NAPA modulates IKKα nuclear localization, phosphorylation of Histone 3 (Ser10) and expres-
sion of nf-κB/Rel proteins in chondrocytes.  NAPA reduces IKKα nuclear localization. In our 
experimental model, the immunofluorescence studies confirmed the information available from “The human 
Protein Atlas”: IKKα “is mainly localized to the nucleoplasm and in addition localized to the cytosol and vesicles” 
(https://www.proteinatlas.org/ENSG00000213341-CHUK/cell). Moreover, IL-1β stimulation led to markedly 
increased nuclear expression of IKKα at all time points, while NAPA reduced this increase (Fig. 5A), in keeping 
Figure 4. IL-1β upregulates gene expression of some selected NF-κB/Rel proteins in chondrocytes and 
synoviocytes. NAPA counteracts this effect in chondrocytes. Left graphs: NFKB1 (p105_50), NFKBIA and 
RELA (p65), gene expression in chondrocytes; middle graphs: NFKB1 (p105_50), NFKBIA and RELA (p65) 
gene expression in synoviocytes; right framed picture: western blot showing that at 8 hours NAPA is effective 
in reducing the protein expression of both the p105 precursor and the p50 NF-κB monomer. [mean ± standard 
deviation; chondrocytes: n = 8 (4 experiments in duplicate); synoviocytes: n = 4 (2 experiments in duplicate)]. 
At each time point of NAPA treatment (8, 24 and 48 hours), the means of groups (CTR, IL-1β treated and 
IL-1β + NAPA treated samples) were compared by ANOVA, followed by Tukey’s post hoc test. Different 
symbols were used for different comparisons: #P < 0.05; ##P < 0.01 and ###P < 0.001 were used to score the degree 
of significance of the differences of either IL-1β treatment or IL-1β + NAPA treatment compared to the control 
condition and *P < 0.05; **P < 0.01; and ***P < 0.001 for IL-1β treatment compared to the IL-1β + NAPA 
treatment.
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with previous in vitro studies performed with chondrocytic cell lines5. The strong nuclear localization is highly 
suggestive of prevalent chromatin activity of IKKα in this experimental model.
NAPA reduces the levels of H3ser10 phosphorylation. Among the IKKα activities performed in the nucleus, 
a relevant one in the context of the inflammatory stimuli is the phosphorylation of serine 10 of histone H3 
Figure 5. IL-1β increases IKKα nuclear translocation and phosphorylation of serine 10 on histone H3, 
while NAPA attenuates these signalling events. (A) Overlapping signals of nuclear counterstaining (DAPI) 
and IKKα detected via an Alexa Fluor 555 secondary antibody: the colocalized signals indicate that NAPA 
addition is effective in reducing nuclear translocation of IKKα. (B) Upper pictures: left, western blot of anti-
phosphorylated serine 10 of histone H3, along with GAPDH as a loading control and right: densitometric 
analysis of the signal showing the different pattern of H3pSer10 accumulation in CTR (circle), IL-1β (square) 
or IL-1β + NAPA (triangle) conditions. Lower images: specificity of the signal obtained with the anti-H3 
phosphorylated serine 10: 20x field pictures of chondrocytes grown on coverslips in the bottom of wells at time 
0 in control (upper row) or IL-1β stimulated conditions (lower row): Green: IKKα detected with an Alexa Fluor 
488 anti-rabbit antibody; red: H3pSer10 signal detected with an Alexa Fluor 555 anti-mouse antibody; blue: 
nuclear DNA stained with Hoechst 33342 and merged images.
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(H3Ser10)32. Therefore, we performed an analysis of this chromatin modification by western blot, followed by 
densitometric analysis, and confirmed the specificity of the signal by immunofluorescent staining and positive 
cell counts.
Western blot analysis allowed us to evaluate the kinetic pattern of the phosphorylation of H3Ser10. At T0, 
phosphorylated H3Ser10 (H3pSer10) signal appeared evident in the CTR group, in keeping with the basal inflam-
matory condition of hyperconfluent OA chondrocytes but was markedly increased in the IL-1β group, where the 
cells had been kept under inflammatory stimulation for one week (Fig. 5B).
It is conceivable that the inflammatory networks in the co-cultures are sustained by both paracrine and auto-
crine loops, whose weight increases during the experiment, possibly leading, at later times, to biases in evaluat-
ing both IL-1β effects and counteracting activity of NAPA. Therefore, the more reliable results are those within 
24 hours of medium change. Moreover, previous studies showed that hyperconfluent differentiated chondrocytes 
present basal activation of p38 MAPK33, another kinase responsible for H3pSer10 34. Therefore, the effect of IL-1β 
needs to be assessed as an enhancement of a basal inflammatory state. The kinetic patterns of H3pSer10 are dif-
ferent in control or IL-1β-stimulated chondrocytes with or without NAPA, indicating a progressive accumulation 
of the signal in control conditions, while a biphasic pattern was observed following IL-1β stimulation (Fig. 5B, 
upper western blot pictures), in keeping with literature34,35. At time 0, the cells previously treated with IL-1β had 
a high level of H3pSer10, which markedly decreased at time 8, while NAPA almost completely abolished this 
signal. Notably, at all time points, NAPA reduces IKKα nuclear translocation. This decrease seems sufficient to 
affect transcription of the above-mentioned genes, whose expression is indeed significantly reduced by NAPA, 
mostly at T24, despite, in most cases, a trend of reduction already appreciated at T8. At 24 hours, we observed a 
second wave of H3Ser10 phosphorylation, and NAPA again reduced this signal. This finding is consistent with the 
significantly decreased transcription of most target genes at T24.
The analysis of H3pSer10 immunofluorescent staining was carried out in an additional experiment performed 
with cells plated onto glass coverslips and mostly focused on investigating the pattern of the staining and any 
differences among cells grown with or without synoviocytes plated onto transwells. Culture on coverslips allowed 
accurate evaluation by confocal microscopy, but because of differences in cell behaviour when cultured on either 
plastic or glass surfaces, we matched the functional analysis reported above to the results obtained with western 
blotting. Nevertheless, the mean percentage of positive cells at T0, after counting many hundreds of cells in sev-
eral 20x fields, confirmed double the number (mean ± SD) under IL-1β stimulation (Fig. 5B, lower images): CTR 
T0 4.6 ± 3.2 and IL-1β T0 8.3 ± 5.3.
The observation of H3pSer10 immunofluorescent staining in OA chondrocytes either in single culture or 
co-culture conditions intriguingly revealed mitotic activity only in the absence of synoviocytes (Fig. 6). Bright 
pictures of chromosomes in prophase were quite frequent when synoviocytes were absent. Conversely, the inter-
action between the two cell populations seemed to inhibit chondrocyte proliferation and instead sustained the 
inflammatory state, characterized by a clear nuclear H3pSer10 signal associated with a widespread but mostly 
nuclear IKKα signal (Figs 5B and 6). This effect strongly points to the added value of exploring the effects of 
NAPA using the co-culture model, thus obtaining information closer to the microenvironment of an OA joint.
NAPA reduces the levels of selected NF-κB/Rel proteins. The western blot shown in Fig. 4 again indicates that the 
most evident results are obtained at 8 hours and clearly points to IL-1β induction of both the p105 precursor and 
the p50 NF-κB monomer at T0 and to a marked reduction exerted by NAPA at T8.
Discussion
State-of-the-art pharmacological approaches to treat OA are focused on the development of safe alternatives 
for the most common drugs used in the clinic to control their frequent negative side effects. Glucosamine and 
its analogues seemed very promising, but their clinical use has shown contradictory results so far20. Among the 
GlcN derivatives, NAPA could represent an interesting breakthrough to fight the inflammation associated with 
OA, but to date, few studies have analysed this molecule that shows chondroprotective roles and inhibitory effects 
on MMP expression in vitro36.
An early in vivo study indicated that NAPA performed better than GlcN in delaying OA progression in a rab-
bit model of experimental OA36, and this was also confirmed by in vitro studies performed with primary rabbit 
chondrocytes.
More recently, the chondroprotective activities of NAPA were confirmed in a murine surgically induced OA 
model: the destabilization of medial meniscus (DMM), recognized as the surgical method of choice for repro-
ducing the slow progression of human OA and for identifying the pivotal OA drug targets, as well as testing novel 
treatments37. In this in vivo study, NAPA was delivered to the mice 4 weeks after the DMM surgery, thus simu-
lating an early stage of osteoarthritic disease7,37. The intra-articular injection of NAPA delayed OA progression 
and preserved cartilage integrity, reducing fibrillation, cell cluster number and the amount of fibrous tissue, in 
lateral and medial femoral condyles and in the tibial plateau of knee joints. The immunohistochemical evidence 
of significantly decreased expression of IKKα in NAPA-treated joints paralleled the decreased expression of 
ADAMTS5, MMP-10, MMP-13 and therefore was in keeping with our previous findings38 about the role of IKKα 
in OA pathophysiology. This result prompted us to undertake the present in vitro study to advance the molecular 
characterization of the underlying mechanisms and mediators and to confirm the NAPA > IKKα connection. For 
this purpose, we performed kinetic evaluations that allowed us to explore and correlate signalling events, gene 
transcription and protein release of many NF-κB target genes with pivotal activity in osteoarthritis39.
Based on previous findings5, we focused our interest on IKKα, the kinase that is required for the activation 
of the so-called “non-canonical” pathway40,41 but is also able to directly regulate the chromatin structure down-
stream of the “canonical” pathway and activate transcription of selected genes through phosphorylation of serine 
10 of histone H3 (H3Ser10)40. Notably, early findings already showed that, compared with IKKβ, IKKα ablation 
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had a broader range of effects on OA chondrocyte physiology42, some of which were kinase- and NF-κB- inde-
pendent and were targeted to the control of ECM remodelling via tuning of MMP-13 activity38 without marked 
effects on MMP-13 gene and protein expression43.
The experimental co-culture model exploited the use of primary human chondrocytes and synoviocytes and 
was selected to better mimic the environment of an OA joint in vitro, with the crosstalk between cartilage and 
synovium44 and therefore was a suitable model for translating the findings to human pathology, as well as disclos-
ing any “site specific” effects. Before any treatment, chondrocytes were allowed to reach high density to recover 
a differentiated chondrogenic phenotype24. To reproduce an inflamed OA joint, the co-cultures were long-term 
stimulated with IL-1β, a recognized OA target validated in DMM31. In these experimental settings, cells from 
either healthy or OA donors behaved in the same way, pointing to the strength of our experimental co-culture 
model and its reliability in reproducing an OA environment, independent of the healthy or OA origin of the joint 
cells. Therefore, we pooled the findings to increase the sample sizes.
Figure 6. Confocal analysis of the differential subcellular patterns of phosphorylation of serine 10 on histone 
H3. Upper images: CTR cells at T0 without co-cultured synoviocytes. Chondrocyte culture without transwells 
showed frequent images of cells undergoing mitosis (left 20x magnification), with strong H3pSer10 signals 
arranged to stain an outer coat around the supercoiled DNA of the chromosomes (right 60x magnifications: 
an optical section of the arranged chromosomes in the upper image and the resulting 3D projection of many 
optical sections in the lower image). Middle images: CTR cells at T0 with co-cultured synoviocytes. Left 20x 
magnification: chondrocyte culture with transwells showed frequent images of cells in interphase with dotted 
nuclear H3pSer10 signals, indicating the activation of NF-κB-regulated promoters. Right 60x magnification: 
an optical section of the nucleus (upper image) and the resulting 3D projection of many optical sections 
(lower image). Bottom images: IL-1β cells at T0 with co-cultured synoviocytes. Left 20x magnification: IL-1β-
stimulated chondrocyte culture with transwells showed more frequent images of cells in interphase with nuclear 
H3pSer10 signals, indicating increased activation of NF-κB-regulated promoters. Right 60x magnification: an 
optical section of the nucleus (upper image) and the resulting 3D projection of many optical sections (lower 
image).
1 2Scientific RepoRtS |         (2019) 9:13603  | https://doi.org/10.1038/s41598-019-49188-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
To gain insight into the signalling events, we evaluated the trend of H3Ser10 phosphorylation by western 
blot and confirmed specificity by immunofluorescence, selecting the early experimental time points (0, 8 and 
24 hours). Moreover, to assess synoviocyte contribution to the inflammatory environment, we also performed 
immunofluorescence experiments to compare the phosphorylated H3Ser10 pattern of plain chondrocytes with 
that of chondrocytes in co-culture with synoviocytes and found that synoviocytes enhance an “inflammatory” 
H3pSer10 pattern. Indeed, as previously reviewed45, phosphorylated H3Ser10 antibody brilliantly marks chro-
mosome condensation in cell division, while in interphase, chromatin relaxation required to allow transcrip-
tion of NF-κB regulated promoters. Several different kinases may intervene in phosphorylating H3Ser1045, but 
only IKKα “functions in the nucleus to activate the expression of NF-κB responsive genes after stimulation with 
cytokines”. In these conditions, IKKα is recruited to NF-κB-responsive promoters, and there confers a permissive 
arrangement to the chromatin by mediating H3Ser10 phosphorylation and subsequent acetylation of specific res-
idues46. Previous work has described the latency between H3Ser10 phosphorylation and transcription of selected 
genes34: H3Ser10 phosphorylation is, in most cases, a phasic event that upon inflammatory cytokine stimulation 
tags some NF-κB-regulated promoters and shortly precedes the start of transcription34 of genes encoding for 
inflammatory mediators, thus leading to an “autocrine” enhancement of NF-κB signalling.
However, the cells have developed molecular mechanisms whereby they downregulate inflammation. Our 
findings indeed highlighted an overall irregular trend in the gene expression of most inflammatory markers 
under IL-1β stimulation, which peaked at T24 but decreased at 48 hours, possibly because of negative feedback 
loops35 or receptor desensitization47. Notably, in these experimental settings at 24 hours, NAPA significantly 
decreased the gene expression of ADAMTS5, IL-6 and MCP-1 in one or both cell types compared to the IL-1β 
stimulated samples. NFKB1 (p105-p50) and IL-6 are important NF-κB target genes27 whose reduction points to 
effective inhibition of the NF-κB signalling pathway exerted by NAPA at the early time points.
Despite the difficulty in exactly defining the timing of gene transcription after chromatin activation26,34, the 
aforementioned results could be related, at least partially, to what was observed in the western blot analysis of 
H3Ser10 phosphorylation in the chondrocytes. The kinetics of H3Ser10 phosphorylation show a different trend 
among CTR cells and cells stimulated with IL-1β, either with or without NAPA. At time 0, the cells previously 
treated with IL-1β had a high level of H3pSer10, which markedly decreased at time 8, while NAPA almost com-
pletely abolished this signal. It is likely that this effect is dependent on the ability of NAPA to reduce IKKα nuclear 
translocation, as shown by immunofluorescent experiments. This ability seems sufficient to affect transcription 
of the above-mentioned genes, whose expression is indeed significantly reduced, mostly at T24, despite, in most 
cases, a trend of reduction that is already appreciated at T8. At 24 hours, we observed a second wave of H3Ser10 
phosphorylation, and NAPA again reduced this signal. The early effects of NAPA in reducing transcription at T8 
are possibly quickly reflected in translation since our protein release analysis indicated a significant reduction 
by NAPA of some inflammatory or catabolic effectors, mostly at early time points (T8). However, it is also con-
ceivable that the early effects of NAPA on protein production might be dependent on the medium change per-
formed at the time of NAPA delivery, while later accumulation phenomena might mask these effects. Given our 
experimental settings, in all groups, and for almost all the quantified molecules, we appreciated a time-dependent 
progressively increasing release as proof of the accumulation of the cellular products that hampered the percep-
tion of NAPA effects at later time points. Moreover, accumulating evidence indicates that despite the pivotal role 
of the NF-κB signalling pathway in OA, involvement of other signalling pathways may occur downstream in 
chondrocytes in response to stimulation with IL-1β48. Interaction between the NF-κB and the Notch pathway has 
been recently reviewed49, and perhaps the differential ability of NAPA to counteract transcription and translation 
of a given gene may depend on the prevalent or accessory role of NF-κB in that process. Notably, MCP-1 was 
significantly reduced in the presence of NAPA at T8. Milder, not statistically significant effects were observed for 
RANTES, MIP-1α and β and metalloproteases, such as MMP13 and MMP7.
The role of chemokines in OA has been recently reviewed and disclosed based on cumulative evidence derived 
from both findings obtained in patients and evidence obtained in animal models of OA. The severity of human 
OA, as assessed by the mean of the radiological score, has been found to be correlated with the levels in synovial 
fluid of selected chemokines that include those analysed in our study, i.e., the CCR2 ligand (CCL2/MCP-1) and 
CCR5 ligands (CCL3/MIP-1α, CCL4/MIP-1β, and CCL5/RANTES)50. Particularly, CCL2/MCP-1 is the major 
chemokine active in macrophage recruitment and therefore plays a role in the activation of innate immunity, now 
recognized to contribute to OA pathogenesis. The pivotal role of this chemokine in OA development is confirmed 
by an early increase in CCL2 transcription that follows two surgical OA models: the murine DMM51 and the rat 
meniscal tear models52. CCL2/MCP-1 serum levels were correlated with both pain scores53 and with radiographic 
progression of OA54. A recent report that combined human findings ex vivo with results from DMM mice further 
confirmed a key role of MCP-1 in mediating monocyte recruitment, inflammation and cartilage destruction55 in 
osteoarthritis.
A relevant effect of NAPA is the modulation of ADAMTS5, the foremost cartilage ECM-degrading enzyme 
responsible for aggrecan removal in the early phase of the disease56. This pivotal role is confirmed by the effective-
ness of inhibiting OA progression by a treatment of this catabolic enzyme by small interfering RNA56. Notably, 
ADAMTS5 is an OA drug target validated with the DMM model31, and indeed, its antibody-mediated neu-
tralization has proven able to inhibit OA progression in a DMM model57. The ability of NAPA to inhibit tran-
scription and release of multiple inflammatory mediators and catabolic enzymes in human primary joint cells 
further points to this drug as a suitable candidate for the therapeutic treatment of OA. A careful refinement of the 
delivery schedule of this drug or slow releasing strategies would be needed for the long-term maintenance of its 
anti-inflammatory and anti-catabolic activity.
The pattern of transcription upon IL-1β stimulation, with or without NAPA, was similar in both cell types 
in some cases (such as for IL-6), but overall, we observed that chondrocytes had a higher IL-1β induction and a 
stronger NAPA modulation, thus pointing at “site specific” effects.
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We previously described the differential involvement of cartilage and synovium in the pathogenesis of either 
osteoarthritis or inflammatory arthritis, based on the co-localization of IL-1β, TNFα and iNOS58, suggesting 
NF-κB activation in either the cartilage or the synovium since the three markers are direct NF-κB targets27. The 
primary role of cartilage in driving joint derangement in OA has also been recently confirmed59. On the other 
hand, as was recently reviewed60, histopathological studies have documented changes of progressively increasing 
severity in synovial samples derived from patients with different OA grades compared with normal synovium, 
which consists of a thin lining layer an a loose connective tissue subintimal layer. Changes range from synovial 
lining hyperplasia, villous hyperplasia, fibrosis and infiltration of perivascular mononuclear cells that give rise to 
the infiltrating macrophages that may be found in both the subintimal layer and in the perivascular infiltrates, 
where they are also able to recruit T and B lymphocytes.
Thus, in OA synovial samples, both fibroblast-like and macrophage cells are present, with a higher percentage 
of the latter in moderate- compared to low-grade synovitis. The behaviour of the cells derived from the synovial 
samples changes with regard to the composition of prevalent fibroblasts or mixed fibroblasts/macrophages61. 
In keeping with their higher prevalence in more advanced stages of the disease, synovial macrophages indeed 
show a higher level of inflammation, with stronger release of chemokines and alarmins compared to the synovial 
fibroblasts.
In the present study, we used human fibroblast-like synoviocytes of both normal and OA origin (https://www.
cellapplications.com/human-fibroblast-synoviocytes-hfls). Therefore, we have been working with cells that are 
closer to the cells of the lining layer, the only synovial component present in the early stages of the disease that are 
just a bystander of the damage that is initially triggered in the cartilage and then involves the synovium44.
Data Availability
The data reported in this study are available from the corresponding author.
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